Teva Announces Approval of Three-Times-A-Week COPAXONE® 40 mg/mL in Russia for the Treatment of Relapsing-Remitting Multiple Sclerosis Teva, 8 Oct 2015 Accessed on 13 Oct 2015 from http://ir.tevapharm.com/phoenix.zhtml?c=73925&p=irol-newsArticle&ID=2095367. CommentRecommendBookmarkWatch